Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by Analysts
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by Analysts
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have received a consensus rating of "Hold" from the eight research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.71.
据MarketBeat报道,Atara BioTreateutics,Inc.(纳斯达克代码:ATRA-GET Rating)的股票已获得覆盖该股票的八家研究公司的共识评级为持有。两名分析师对该股的评级为卖出建议,三名分析师给出了持有建议,两名分析师对该公司提出了买入建议。在过去一年对该股进行评级的券商中,12个月目标价的平均水平为18.71美元。
ATRA has been the topic of a number of recent research reports. The Goldman Sachs Group dropped their price objective on Atara Biotherapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Tuesday, August 9th. Mizuho decreased their price objective on Atara Biotherapeutics from $39.00 to $31.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th. Finally, StockNews.com started coverage on Atara Biotherapeutics in a report on Wednesday, October 12th. They set a "hold" rating on the stock.
全反式维甲酸是最近一些研究报告的主题。在8月9日星期二的一份报告中,高盛夫妇将Atara BioTreateutics的目标价从4.00美元下调至3.00美元,并对该股设定了“卖出”评级。瑞穗将Atara BioTreateutics的目标价从39.00美元下调至31.00美元,并在8月16日(星期二)的一份报告中对该股设定了“买入”评级。最后,StockNews.com在10月12日星期三的一份报告中开始报道Atara BioTreateutics。他们对该股设定了“持有”评级。
Atara Biotherapeutics Stock Performance
Atara BioTreatetics股票表现
ATRA stock opened at $4.65 on Tuesday. The company has a market capitalization of $441.19 million, a price-to-earnings ratio of -1.88 and a beta of 1.00. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $18.31. The stock has a fifty day moving average of $4.30 and a 200-day moving average of $4.74.
ATRA股票周二开盘报4.65美元。该公司市值为4.411亿美元,市盈率为-1.88倍,贝塔系数为1.00。Atara BioTreateutics的股价为2.83美元,为52周低点,52周高点为18.31美元。该股的50日移动均线切入位为4.30美元,200日移动均线切入位为4.74美元。
Insider Transactions at Atara Biotherapeutics
Atara BioTreateutics的内幕交易
Institutional Trading of Atara Biotherapeutics
Atara生物疗法的机构交易
Several hedge funds have recently bought and sold shares of ATRA. Envestnet Asset Management Inc. bought a new stake in Atara Biotherapeutics during the first quarter valued at about $112,000. New York State Common Retirement Fund boosted its stake in shares of Atara Biotherapeutics by 11.5% in the first quarter. New York State Common Retirement Fund now owns 64,445 shares of the biotechnology company's stock worth $599,000 after acquiring an additional 6,664 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Atara Biotherapeutics in the first quarter worth about $220,000. Teacher Retirement System of Texas boosted its stake in shares of Atara Biotherapeutics by 12.6% in the first quarter. Teacher Retirement System of Texas now owns 15,447 shares of the biotechnology company's stock worth $144,000 after acquiring an additional 1,728 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Atara Biotherapeutics by 12.5% in the first quarter. Swiss National Bank now owns 177,700 shares of the biotechnology company's stock worth $1,651,000 after acquiring an additional 19,800 shares during the period.
几家对冲基金最近买卖了ATRA的股票。Envestnet Asset Management Inc.在第一季度购买了Atara BioTreateutics的新股份,价值约为11.2万美元。纽约州共同退休基金在第一季度将其在Atara BioTreateutics的股份增加了11.5%。纽约州共同退休基金现在拥有这家生物技术公司64,445股股票,价值599,000美元,在此期间又购买了6,664股。Qube Research&Technologies Ltd在第一季度购买了Atara BioTreateutics的新头寸,价值约22万美元。德克萨斯州教师退休系统在第一季度将其在Atara BioTreateutics的股份增加了12.6%。德克萨斯州教师退休系统在此期间额外购买了1,728股,现在拥有15,447股这家生物技术公司的股票,价值14.4万美元。最后,瑞士国家银行在第一季度增持了Atara BioTreateutics的股份12.5%。瑞士国家银行目前持有这家生物技术公司177,700股股票,价值1,651,000美元,在此期间又购买了19,800股。
About Atara Biotherapeutics
Atara生物疗法公司简介
(Get Rating)
(获取评级)
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
Atara BioTreateutics,Inc.是一家同种异体T细胞免疫疗法公司,该公司率先为包括实体瘤、血液病和自身免疫性疾病在内的严重疾病患者开发变革性疗法。还为高度未得到满足的医疗需求的患者提供现成的治疗。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
- 免费获取StockNews.com关于Atara生物疗法(ATRA)的研究报告
- CrowdStrike抛售:投资者罢工的时候到了
- Pure Storage是稳步增长的存储业务
- 特斯拉股价下滑,原因如下
- 内部人士和机构收购Fastenal,成为未来的贵族
- 大地块是不是正在酝酿中的下一个床上沐浴和超越灾难?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得Atara生物疗法日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Atara BioTreateutics和相关公司的最新新闻和分析师评级的每日简要摘要。